McAfee SECURE sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams
Call Us Toll Free
877.880.5251
Newsletter
Doctor Endorsements
Our practice has been recommending VisiVite Dry Eye Relief TG-1000 to every dry eye patient we see. The patients love it. They feel a great relief from not having to constantly feel a burning or itching sensation and being free of hourly tear drops. Our practice recommends these products to everyone!
Monique M. Barbour, M.D.
Ophthalmologist
READ MORE >
We see approximately 120 patients per week with about 15% having or being at risk for macular degeneration. Using the AREDS as our reference we became aware of the importance of nutritional supplements in the prevention of the progression of macular degeneration. This along with various other studies on the importance of vitamins for general eye health and AREDS2 prompted us to look for a supplement that fit the needs of our patients. Visivite showed itself to be the only company who took pains to offer the ratio of different vitamins supported by this research.
Dr. Kendal Piatt, O.D.
Optometrist
READ MORE >
We have been recommending VisiVite for several years. AREDS2 formulation vitamins are the mainstay in the treatment of dry AMD which affects about 1.7 million Americans. We find that the VisiVite vitamins fit the needs of our patients. We can recommend different formulations based on the patients' history. The quality is unsurpassed, they are well tolerated which increases patient compliance. At "Island Retina" our mission statement is to provide outstanding retinal care in a warm and supportive environment. I have been practicing for more than 20 years. We love taking care of patients with retinal disease including diabetes, macular degeneration and retinal detachments. Our practice is unique in that we have a surgery center,we are involved in several national research projects as well as our own research, and we have a satelite office in Commack, NY. I do a great deal of lecturing throughout the country as part of my committment to education.
Pamela Weber, M.D.
Retinal Surgeon
READ MORE >
East Florida Eye Institute specializes in the treatment of Macular Degeneration, Glaucoma, Diabetic Eye Disease, and Dry Eye Disease. We recommend the use of VisiVite for all of our Macular Degeneration patients.
Ronald E. P. Frenkel, M.D.
Ophthalmologist
READ MORE >
We recommend that all of our patients take VisiVite AREDS2-based vitamins, due to the evidence based nature of the formula.
Marc Lay, OD
Optometrist
READ MORE >
I've been in practice for 36 years. We see many patients with Macular Degeneration and dry eyes. As a general Ophthalmologist, I see patients with varying Eye problems including cataracts and glaucoma. Based on the AREDS2 study, a vitamin like Visivite is the only treatment for Macular Degeneration available today.
Martin L Weinhoff, MD
Ophthalmologist
READ MORE >
This combination of nutrients, found in supplements like Ocuvite and VisiVite, is now widely recommended for people with moderate or severe macular degeneration. Current or former smokers may be better off with VisiVite's Smoker's Formula, which leaves out the beta-carotene (beta-carotene supplements my increase the risk of lung cancer in smokers).
Marvin Moe Bell, M.D., M.P.H.
Physician and Author
READ MORE >
I recommend VisiVite to all my macular degeneration patients. Based on the latest AREDS2 study, lutein and zeaxanthin absorption was increased when beta-carotene was eliminated. Therefore, I advise all my AMD patients to take VisiVite AREDS2 Plus+ Gold Formula for maximal protection, as it contains all the necessary ingredients as recommended by this latest research.

Dr. Cohen is a distinguished Fellow of The American Academy of Optometry.
Dr. Madeline Cohen, O.D.
Optometrist, F.A.A.O.
READ MORE >
A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss  
 
AREDS Report No. 8 
 
Age-Related Eye Disease Study Research Group

Background  Observational and experimental data suggest that antioxidant and/or zinc supplements may delay progression of age-related macular degeneration (AMD) and vision loss.

Objective  To evaluate the effect of high-dose vitamins C and E, beta carotene, and zinc supplements on AMD progression and visual acuity.

Design  The Age-Related Eye Disease Study, an 11-center double-masked clinical trial, enrolled participants in an AMD trial if they had extensive small drusen, intermediate drusen, large drusen, noncentral geographic atrophy, or pigment abnormalities in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye. At least 1 eye had best-corrected visual acuity of 20/32 or better. Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.

Main Outcome Measures  (1) Photographic assessment of progression to or treatment for advanced AMD and (2) at least moderate visual acuity loss from baseline (15 letters). Primary analyses used repeated-measures logistic regression with a significance level of .01, unadjusted for covariates. Serum level measurements, medical histories, and mortality rates were used for safety monitoring.

Results  Average follow-up of the 3640 enrolled study participants, aged 55-80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52-0.98). The ORs for zinc alone and antioxidants alone are 0.75 (99% CI, 0.55-1.03) and 0.80 (99% CI, 0.59-1.09), respectively. Participants with extensive small drusen, nonextensive intermediate size drusen, or pigment abnormalities had only a 1.3% 5-year probability of progression to advanced AMD. Odds reduction estimates increased when these 1063 participants were excluded (antioxidants plus zinc: OR, 0.66; 99% CI, 0.47-0.91; zinc: OR, 0.71; 99% CI, 0.52-0.99; antioxidants: OR, 0.76; 99% CI, 0.55-1.05). Both zinc and antioxidants plus zinc significantly reduced the odds of developing advanced AMD in this higher-risk group. The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54-0.99). No statistically significant serious adverse effect was associated with any of the formulations.

Conclusions  Persons older than 55 years should have dilated eye examinations to determine their risk of developing advanced AMD. Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.

Arch Ophthalmol. 2001;119:1417-1436


Charities We Support
VisiviteVisiviteVisiviteAREDSFloraGLOONSCRNMSSMRPBColumbioa University